Ticker
$ALEC
1 catalyst touching ALEC in the last 60 days, newest first, each with the price move that followed.
- 78
Alector licenses AL050 GCase program to Genentech for $100M upfront plus $1.17B milestones
Alector granted Genentech exclusive worldwide rights to develop and commercialize its AL050 brain-penetrant glucocerebrosidase enzyme replacement therapy, with Alector receiving $100 million upfront and up to $1.17 billion in development, regulatory, and commercial milestone payments plus tiered royalties on net sales. This represents a significant licensing transaction monetizing a key pipeline asset, though the upfront payment is moderate relative to a biotech's market cap and the deal retains Alector's platform for other applications.
ALEC ▲SEC 8-K · 5 Oct 2026, 11:00 UTC
Information only. AURA does not give buy or sell recommendations.